Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galapagos NV

26.86
+0.37001.40%
Post-market: 26.860.00000.00%16:34 EDT
Volume:384.34K
Turnover:10.29M
Market Cap:1.77B
PE:-9.66
High:26.98
Open:26.62
Low:26.50
Close:26.49
Loading ...

Company Profile

Company Name:
Galapagos NV
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
704
Office Location:
Generaal De Wittelaan L11 A3,Mechelen,Antwerp,Belgium
Zip Code:
2800
Fax:
32 1 534 29 01
Introduction:
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Directors

Name
Position
Onno van de Stolpe
Director and Chief Executive Officer
Rajesh Parekh
Chairman of the board
Daniel O'Day
Director
Howard Rowe
Director
Katrine Bosley
Director
Linda Higgins
Director
Mary Kerr
Director
Peter Guenter
Director

Shareholders

Name
Position
Onno van de Stolpe
Director and Chief Executive Officer
Bart Filius
Chief Financial Officer & Chief Operating Officer
Andre Hoekema
Chief Business Officer
Piet Wigerinck
Chief Scientific Officer
Walid Abi Saab
Chief Medical Officer